Hollsteen
← Jabil

Equity incl. NCI

Balance – as of period end · $M

QuartersFiscal years

$MEquity incl. NCI · Q1 FY2016: $2.4B · 10-Q 0001193125-16-422561 filed Jan 6, 2016Equity incl. NCI · Q2 FY2016: $2.5B · 10-Q 0001193125-16-530833 filed Apr 5, 2016Equity incl. NCI · Q3 FY2016: $2.5B · 10-Q 0001193125-16-638261 filed Jun 30, 2016Equity incl. NCI · Q4 FY2016: $2.5B · 10-K 0001193125-16-742815 filed Oct 20, 2016Equity incl. NCI · Q1 FY2017: $2.4B · 10-Q 0001193125-17-005745 filed Jan 9, 2017Equity incl. NCI · Q2 FY2017: $2.4B · 10-Q 0001193125-17-111778 filed Apr 5, 2017Equity incl. NCI · Q3 FY2017: $2.3B · 10-Q 0001193125-17-219901 filed Jun 30, 2017Equity incl. NCI · Q4 FY2017: $2.4B · 10-K 0001193125-17-313834 filed Oct 19, 2017Equity incl. NCI · Q1 FY2018: $2.3B · 10-Q 0001193125-18-002956 filed Jan 4, 2018Equity incl. NCI · Q2 FY2018: $2.3B · 10-Q 0001193125-18-108777 filed Apr 5, 2018Equity incl. NCI · Q3 FY2018: $2.2B · 10-Q 0001193125-18-207639 filed Jun 28, 2018Equity incl. NCI · Q4 FY2018: $2.0B · 10-K 0001193125-21-305429 filed Oct 22, 2021Equity incl. NCI · Q1 FY2019: $1.9B · 10-Q 0001193125-19-005404 filed Jan 9, 2019Equity incl. NCI · Q2 FY2019: $1.9B · 10-Q 0001193125-19-097892 filed Apr 4, 2019Equity incl. NCI · Q3 FY2019: $1.9B · 10-Q 0001193125-19-186025 filed Jun 28, 2019Equity incl. NCI · Q4 FY2019: $1.9B · 10-K 0001193125-19-271646 filed Oct 22, 2019Equity incl. NCI · Q1 FY2020: $1.8B · 10-Q 0001193125-20-001434 filed Jan 3, 2020Equity incl. NCI · Q2 FY2020: $1.8B · 10-Q 0001193125-20-094625 filed Apr 1, 2020Equity incl. NCI · Q3 FY2020: $1.6B · 10-Q 0001193125-20-183269 filed Jun 29, 2020Equity incl. NCI · Q4 FY2020: $1.8B · 10-K 0001193125-20-274411 filed Oct 22, 2020Equity incl. NCI · Q1 FY2021: $2.0B · 10-Q 0001193125-21-004678 filed Jan 8, 2021Equity incl. NCI · Q2 FY2021: $2.1B · 10-Q 0001193125-21-104662 filed Apr 2, 2021Equity incl. NCI · Q3 FY2021: $2.1B · 10-Q 0001193125-21-207682 filed Jul 2, 2021Equity incl. NCI · Q4 FY2021: $2.1B · 10-K 0001193125-21-305429 filed Oct 22, 2021Equity incl. NCI · Q1 FY2022: $2.2B · 10-Q 0001193125-22-004029 filed Jan 7, 2022Equity incl. NCI · Q2 FY2022: $2.3B · 10-Q 0001193125-22-092806 filed Apr 1, 2022Equity incl. NCI · Q3 FY2022: $2.4B · 10-Q 0001193125-22-186715 filed Jul 1, 2022Equity incl. NCI · Q4 FY2022: $2.5B · 10-K 0001193125-22-268383 filed Oct 25, 2022Equity incl. NCI · Q1 FY2023: $2.5B · 10-Q 0001193125-23-003543 filed Jan 6, 2023Equity incl. NCI · Q2 FY2023: $2.7B · 10-Q 0001193125-23-091542 filed Apr 5, 2023Equity incl. NCI · Q3 FY2023: $2.7B · 10-Q 0001193125-23-179422 filed Jun 30, 2023Equity incl. NCI · Q4 FY2023: $2.9B · 10-K 0001193125-23-259599 filed Oct 20, 2023Equity incl. NCI · Q1 FY2024: $2.5B · 10-Q 0001193125-24-004852 filed Jan 9, 2024Equity incl. NCI · Q2 FY2024: $2.7B · 10-Q 0001628280-24-014951 filed Apr 5, 2024Equity incl. NCI · Q3 FY2024: $2.3B · 10-Q 0001628280-24-031429 filed Jul 9, 2024Equity incl. NCI · Q4 FY2024: $1.7B · 10-K 0001628280-24-043960 filed Oct 28, 2024Equity incl. NCI · Q1 FY2025: $1.6B · 10-Q 0001628280-25-001058 filed Jan 10, 2025Equity incl. NCI · Q2 FY2025: $1.4B · 10-Q 0001628280-25-017004 filed Apr 8, 2025Equity incl. NCI · Q3 FY2025: $1.3B · 10-Q 0001628280-25-033410 filed Jun 30, 2025Equity incl. NCI · Q4 FY2025: $1.5B · 10-K 0001628280-25-045293 filed Oct 17, 2025Equity incl. NCI · Q1 FY2026: $1.3B · 10-Q 0001628280-26-001450 filed Jan 9, 2026Equity incl. NCI · Q2 FY2026: $1.3B · 10-Q 0001628280-26-024148 filed Apr 8, 2026Equity incl. NCI · Q3 FY2026: $1.3B · 10-Q 0001628280-26-046138 filed Jun 30, 20261,3472,4012,867Q1 FY2016Q3 FY2026
$MEquity incl. NCI · Q4 FY2024: $1.7B · 10-K 0001628280-24-043960 filed Oct 28, 2024Equity incl. NCI · Q1 FY2025: $1.6B · 10-Q 0001628280-25-001058 filed Jan 10, 2025Equity incl. NCI · Q2 FY2025: $1.4B · 10-Q 0001628280-25-017004 filed Apr 8, 2025Equity incl. NCI · Q3 FY2025: $1.3B · 10-Q 0001628280-25-033410 filed Jun 30, 2025Equity incl. NCI · Q4 FY2025: $1.5B · 10-K 0001628280-25-045293 filed Oct 17, 2025Equity incl. NCI · Q1 FY2026: $1.3B · 10-Q 0001628280-26-001450 filed Jan 9, 2026Equity incl. NCI · Q2 FY2026: $1.3B · 10-Q 0001628280-26-024148 filed Apr 8, 2026Equity incl. NCI · Q3 FY2026: $1.3B · 10-Q 0001628280-26-046138 filed Jun 30, 20261,3471,3271,737Q4 FY2024Q3 FY2026
Q1 FY2026
1,347$M
All values (43)
PeriodValue ($M)Status
Q3 FY20261,327reported
Q2 FY20261,349reported
Q1 FY20261,347reported
Q4 FY20251,517reported
Q3 FY20251,287reported
Q2 FY20251,358reported
Q1 FY20251,593reported
Q4 FY20241,737reported
Q3 FY20242,276reported
Q2 FY20242,658reported
Q1 FY20242,536reported
Q4 FY20232,867reported
Q3 FY20232,737reported
Q2 FY20232,674reported
Q1 FY20232,530reported
Q4 FY20222,452reported
Q3 FY20222,357reported
Q2 FY20222,338reported
Q1 FY20222,207reported
Q4 FY20212,137reported
Q3 FY20212,139reported
Q2 FY20212,102reported
Q1 FY20211,994reported
Q4 FY20201,825reported
Q3 FY20201,645reported
Q2 FY20201,759reported
Q1 FY20201,849reported
Q4 FY20191,901reported
Q3 FY20191,867reported
Q2 FY20191,859reported
Q1 FY20191,906reported
Q4 FY20181,962reported
Q3 FY20182,186reported
Q2 FY20182,294reported
Q1 FY20182,345reported
Q4 FY20172,368reported
Q3 FY20172,343reported
Q2 FY20172,427reported
Q1 FY20172,392reported
Q4 FY20162,457reported
Q3 FY20162,511reported
Q2 FY20162,485reported
Q1 FY20162,401reported

CSV with all sources · Technical ID: equity_total

More metrics for Jabil

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Operating income by segment

Sources & calculation
Value
$1.3B
Period
Q1 FY2026, ended Nov 30, 2025 · as of Nov 30, 2025 (balance as of date, not a sum)
Source
10-Q, filed Jan 9, 2026 · 0001628280-26-001450
Location
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$1.3BJan 9, 202610-Q 0001628280-26-001450reported · confidence 1. · current